Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENPAD genotype-guided antithrombotic treatment study in peripheral arterial disease
NL-OMON59370Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of carbasalate calcium, clopidogrel and rivaroxaban in arteriosclerosis obliterans (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Occurrence of adverse clinical events related to arterial thrombosis at 24 months, Major adverse cardiovascular events and 1 more. Started Dec 2024; status: completed.
02
Drugs
carbasalate calciumclopidogrelrivaroxaban
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on NL-OMON59370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59370.